Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer

了解和利用共价 KRASG12C 抑制剂对 KRASG12C 突变非小细胞肺癌的免疫调节作用

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT Oncogenic KRASG12C (KG12C) mutations underpin the development of ~13% of non-squamous non-small cell lung cancer (NSCLC) and account for ~10,000 deaths annually in the U.S. The development of potent, selective and clinically active covalent inhibitors of the KG12C oncoprotein represents one of the most exciting recent advances in the field of targeted cancer therapy, yet strategies to circumvent the development of adaptive resistance and improve the durability of individual responses to KG12C inhibitors are urgently needed in order to transform clinical outcomes for patients. In addition to their tumor cell-intrinsic effects, KG12C inhibitors recondition the tumor immune microenvironment in preclinical models and synergize with anti-PD-1 therapy to promote long-term tumor regressions and immunological memory. The mechanisms that underpin KG12C inhibitor-triggered immune pathway activation in KG12C NSCLC are poorly understood. Furthermore, the optimal combinations of KG12C inhibitors with standard of care (SOC) first-line NSCLC systemic therapies including platinum-doublet chemotherapy, PD-1 inhibitor monotherapy and chemo-immunotherapy in order to maximize antitumor immunity have not been established. Furthermore, the impact of co-occurring genomic alterations in STK11/LKB1, KEAP1, TP53 and RBM10 – that shape the immune contexture of KRAS-mutant NSCLC and modify its response to PD- 1 axis blockade – on the clinical efficacy and immunological sequelae of KG12C inhibitor-based therapeutic combinations has not been systematically examined. Based on our preliminary findings and previous work we hypothesize that: 1. Induction of immunogenic cell death contributes to KG12C inhibitor-triggered immune pathway activation in KG12C NSCLC; 2. KG12C inhibitors exhibit immune-sensitizing effects that can be further enhanced with the addition of chemotherapy and/or immune checkpoint inhibitors (ICI); 3. Co-occurring genomic alterations impact both clinical and immunological responses to KG12C inhibitor mono- and combination therapy in KG12C NSCLC. In Aim 1, we will dissect mechanisms and molecular determinants of KG12C inhibitor-mediated immune sensitization in KG12C NSCLC. In Aim 2, we will evaluate synergistic KG12C inhibitor interactions with standard of care first-line systemic therapies (including platinum-doublet chemotherapy, PD-(L)1 inhibitor monotherapy and chemo-immunotherapy) in immune-competent mouse models of KG12C-mutant NSCLC. In Aim 3, we will validate treatment-induced changes in the KG12C NSCLC immune contexture at whole-tumor and single-cell resolution using clinical samples from patients with surgically resected KG12C NSCLC who were treated with neo-adjuvant AMG 510 in combination with platinum-doublet chemotherapy in an investigator-initiated phase 2 clinical trial. Clinical significance: This work will yield fresh insights into mechanisms and determinants of immune pathway activation in response to KG12C inhibitor mono- and combination therapy and will facilitate the development of personalized co-mutation-tailored combination therapeutic strategies that aim to maximize the immune- sensitizing potential and long-term clinical benefit from KG12C inhibitors.
项目概要/摘要 致癌 KRASG12C (KG12C) 突变支撑约 13% 的非鳞状非小细胞肺的发育 癌症 (NSCLC) 每年导致美国约 10,000 人死亡。 KG12C 癌蛋白的临床活性共价抑制剂代表了最新最令人兴奋的进展之一 在靶向癌症治疗领域,还存在规避适应性耐药性和 为了改变临床现状,迫切需要提高个体对 KG12C 抑制剂反应的持久性 患者的结果。除了其肿瘤细胞内在作用外,KG12C 抑制剂还可以修复肿瘤 临床前模型中的免疫微环境并与抗PD-1疗法协同作用以促进长期 肿瘤消退和免疫记忆。 KG12C 抑制剂触发免疫的基础机制 KG12C NSCLC 中的通路激活尚不清楚。此外,KG12C的最佳组合 抑制剂与标准护理 (SOC) 一线 NSCLC 全身疗法,包括铂类双联疗法 化疗、PD-1抑制剂单一疗法和化学免疫疗法,以最大限度地提高抗肿瘤免疫力 尚未成立。此外,STK11/LKB1、KEAP1 中同时发生的基因组改变的影响, TP53 和 RBM10 – 塑造 KRAS 突变 NSCLC 的免疫环境并改变其对 PD 的反应 1 轴阻断——基于 KG12C 抑制剂的治疗的临床疗效和免疫学后遗症 组合尚未经过系统研究。根据我们的初步调查结果和之前的工作,我们 假设: 1. 诱导免疫原性细胞死亡有助于 KG12C 抑制剂触发的免疫途径 KG12C NSCLC 中的激活; 2. KG12C抑制剂表现出可进一步增强的免疫增敏作用 添加化疗和/或免疫检查点抑制剂(ICI); 3.同时发生的基因组改变 影响 KG12C 抑制剂单药和联合治疗的临床和免疫反应 非小细胞肺癌。在目标 1 中,我们将剖析 KG12C 抑制剂介导的免疫的机制和分子决定因素 KG12C NSCLC 的致敏作用。在目标 2 中,我们将评估协同 KG12C 抑制剂的相互作用与标准 一线全身治疗(包括铂类双药化疗、PD-(L)1抑制剂单药治疗和 KG12C 突变 NSCLC 的免疫活性小鼠模型中的化学免疫疗法)。在目标 3 中,我们将验证 在全肿瘤和单细胞分辨率下治疗引起的 KG12C NSCLC 免疫环境变化 使用手术切除的 KG12C NSCLC 患者的临床样本,并接受新辅助治疗 在一项由研究者发起的 2 期临床试验中,AMG 510 与铂类双药化疗相结合。 临床意义:这项工作将为免疫途径的机制和决定因素带来新的见解 KG12C 抑制剂单药和联合疗法的激活,将促进 个性化共突变定制的联合治疗策略,旨在最大限度地提高免疫 KG12C 抑制剂的增敏潜力和长期临床益处。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ferdinandos Skoulidis其他文献

Ferdinandos Skoulidis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ferdinandos Skoulidis', 18)}}的其他基金

Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
RBM10 缺陷型非小细胞肺癌基因组不稳定性触发免疫逃逸的剖析和靶向机制
  • 批准号:
    10658049
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.
剖析和靶向肿瘤-TME 串扰,以预防 NSCLC 中获得性 KRASG12C 抑制剂耐药性。
  • 批准号:
    10634271
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
了解和利用共价 KRASG12C 抑制剂对 KRASG12C 突变非小细胞肺癌的免疫调节作用
  • 批准号:
    10675537
  • 财政年份:
    2021
  • 资助金额:
    $ 37.06万
  • 项目类别:
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
了解和利用共价 KRASG12C 抑制剂对 KRASG12C 突变非小细胞肺癌的免疫调节作用
  • 批准号:
    10276919
  • 财政年份:
    2021
  • 资助金额:
    $ 37.06万
  • 项目类别:

相似海外基金

Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.06万
  • 项目类别:
    Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
  • 批准号:
    2897580
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
    Studentship
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head
自体骨髓抽吸浓缩液治疗股骨头坏死
  • 批准号:
    10658324
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
  • 批准号:
    10794761
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
  • 批准号:
    2304430
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
    Cooperative Agreement
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
  • 批准号:
    MR/X00466X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
    Fellowship
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
  • 批准号:
    23K15543
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
  • 批准号:
    10976161
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
  • 批准号:
    10720234
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
  • 批准号:
    10721983
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了